Other studies have also shown that high expressions of p300 is associated with poor prognosis in several other solid tumors, including non-small cell lung cancers, prostate cancers, breast cancers and laryngeal squamous cell carcinoma subsets45–49. Here, EP300 is linked to prostate carcinoma.